title: Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide.
abstract: BACKGROUND
  Radiation-induced high-grade gliomas are a rare but serious late complication of radiotherapy. We report a patient with radiation-induced cerebellar high-grade glioma who had a durable response to temozolomide.
  
  
  METHODS
  Case report of a 77-year-old woman with a radiation-induced, high-grade cerebellar glioma that responded durably to temozolomide.
  
  
  RESULTS
  Our patient developed a cerebellar high-grade glioma 9 years after treatment for a stage IV (T4N0M0) supraglottic laryngeal squamous cell carcinoma with cisplatinum and fluorouracil chemotherapy, and subsequently focal head and neck radiotherapy. Patient was treated with radiation and concurrent temozolomide (only partially due to toxicity) and was stable for 1 year without further adjuvant treatment. Subsequently the tumor recurred and the patient had a dramatic and durable response to standard 5 day dosing of adjuvant temozolomide.
  
  
  CONCLUSIONS
  High-grade gliomas are a late complication of radiation to the central nervous system and may respond to chemotherapy.
authors.affiliation: Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Monje
authors.forename: Naren R
authors.initials: NR
authors.lastname: Ramakrishna
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Young
authors.forename: Jan
authors.initials: J
authors.lastname: Drappatz
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Doherty
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Santosh
authors.initials: S
authors.lastname: Kesari
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D007822:Laryngeal Neoplasms / Q000532:radiotherapy; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy* / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D049268:Positron-Emission Tomography; D011878:Radiotherapy / Q000009:adverse effects; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide